Novocure's TRIDENT Phase 3 Trial Fails: TTFields Fails to Demonstrate OS Improvement in Newly Diagnosed Glioblastoma, Leading to a 18% Drop in Stock Price
TRIDENT Phase 3 Trial Results: HR 0.953, p=0.519, Failing to Meet Primary Endpoint
Novocure's (NVCR) Tumor Treating Fields (TTFields) device failed to demonstrate improvement in overall survival (OS) in the TRIDENT Phase 3 trial, which involved 981 patients with newly diagnosed glioblastoma (GBM). The median OS in the Early Start Arm (concurrent with chemoradiation) was 17.7 months, and in the Maintenance Start Arm, it was 17.5 months, resulting in a hazard ratio (HR) of 0.953 (p=0.519), which did not achieve statistical significance. This indicates that applying TTFields early in the treatment regimen, concurrent with chemoradiation, does not offer a survival benefit compared to initiating it during the maintenance phase.
Survival Rate Comparison and Subgroup Characteristics
The one-year survival rate was 70.9% in the Early Start Arm versus 72.0% in the Maintenance Start Arm, with two-year rates of 33.9% versus 31.6%, and three-year rates of 22.5% versus 18.4%. There was no substantial difference between the two groups. The median age of the patients was 60 years, with 39% having MGMT promoter methylation, 5% having IDH mutations, and 51% undergoing complete resection, reflecting real-world clinical practice. Notably, approximately 25% of patients in both groups did not initiate maintenance treatment, suggesting that the high early dropout rate in GBM patients may have been a limitation of the trial design.
18% Stock Price Drop and Analyst Reactions
On the day of the announcement, NVCR's stock price plummeted from $17.85 to $14.51, a decrease of 18.16%, reducing the market capitalization to approximately $2.07 billion. Vijay Kumar, an analyst at Evercore ISI, lowered the price target from $23 to $16 but maintained an Outperform rating. The Wall Street average price target was also lowered by $1.00 to $13.50. Despite projected revenue of $655.4 million in 2025 (+8% year-over-year) and $174 million in the first quarter of 2026 (+12% year-over-year), the failure to expand the GBM indication has significantly dampened investor sentiment.
Optune Pax Approval as a Mitigating Factor and Future Pipeline
The FDA's approval of Optune Pax for the treatment of locally advanced pancreatic cancer on February 11, 2026, marking the first new treatment in approximately 30 years, is a positive development. Within two months of launch, over 800 prescriptions were certified, and over 160 prescriptions were filled. Furthermore, the EF-41/KEYNOTE D58 trial is evaluating the combination of Optune with temozolomide and pembrolizumab (Keytruda) in newly diagnosed GBM, with initial data expected in 2029. Detailed data from the TRIDENT trial will be presented at the 2026 ASTRO Annual Meeting.
The failure of the TRIDENT trial has dealt a blow to Novocure's core strategy of expanding the TTFields market beyond its existing Optune approval (recurrent GBM) to include the treatment of newly diagnosed GBM, hindering its ability to gain market share in the global GBM treatment market, which is valued at approximately $3.5 to $3.8 billion (2025-2026). The standard of care for GBM remains surgery, radiation, temozolomide, and maintenance TTFields, and despite the lack of significant breakthroughs in clinical trials based on checkpoint inhibitors (such as nivolumab and pembrolizumab), there remains a significant unmet medical need. From an investment perspective, NVCR's future will depend on the commercial trajectory of Optune Pax (pancreatic cancer) and the results of the EF-41/KEYNOTE D58 Phase 3 trial (GBM + Keytruda, MSD collaboration), which are expected in 2029. Its current cash balance of $448.3 million (end of 2025) mitigates short-term liquidity risks, but its financial flexibility has been reduced by the repayment of a $561 million convertible bond. From a researcher and industry perspective, the combination of TTFields with immune-oncology agents is likely to be a key turning point in the future of GBM treatment, and the ASTRO 2026 detailed subgroup analysis should be closely monitored to identify potential responders, such as those with MGMT promoter methylation.
Source: FierceBiotech (rss)